News
Merck Inc., update to oncology pipeline.
Merck provided updates on their oncology pipeline, focusing on the research and development of potential new medicines for cancer treatment. They highlighted key assets such as the ATR inhibitor tuvusertib and the PARP1 inhibitor M9466, as well as their first-in-class anti-CEACAM5 ADC M9140 and anti-GD2 ADC M3554
The company is exploring various combination studies and clinical trials to advance these innovative treatments for different types of cancers
Type: industry
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
